Buerger's disease laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There are no diagnostic laboratory findings associated with Buerger's disease. Lab testing is done to exclude other vasculitides, such as lupus, scleroderma and mixed connective tissue disease. | There are no diagnostic laboratory findings associated with Buerger's disease. Lab testing is done to exclude other vasculitides, such as [[Systemic lupus erythematosus|lupus]], [[scleroderma]] and [[mixed connective tissue disease]]. | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
*There are no diagnostic laboratory findings associated with Buerger's disease.<ref name=" | *There are no diagnostic laboratory findings associated with Buerger's disease. | ||
*Laboratory testing is performed to exclude other pathologies, and include:<ref name="pmid10995867">{{cite journal |vauthors=Olin JW |title=Thromboangiitis obliterans (Buerger's disease) |journal=N. Engl. J. Med. |volume=343 |issue=12 |pages=864–9 |date=September 2000 |pmid=10995867 |doi=10.1056/NEJM200009213431207 |url=}}</ref><ref name="pmid12710840">{{cite journal |vauthors=Maslowski L, McBane R, Alexewicz P, Wysokinski WE |title=Antiphospholipid antibodies in thromboangiitis obliterans |journal=Vasc Med |volume=7 |issue=4 |pages=259–64 |date=2002 |pmid=12710840 |doi=10.1191/1358863x02vm452oa |url=}}</ref><ref name="pmid20421527">{{cite journal |vauthors=Piazza G, Creager MA |title=Thromboangiitis obliterans |journal=Circulation |volume=121 |issue=16 |pages=1858–61 |date=April 2010 |pmid=20421527 |pmc=2880529 |doi=10.1161/CIRCULATIONAHA.110.942383 |url=}}</ref> | |||
**Acute phase reactants that indicate an active inflammatory process: | **Acute phase reactants that indicate an active inflammatory process: | ||
***[[Erythrocyte sedimentation rate]] | ***[[Erythrocyte sedimentation rate]] | ||
| Line 15: | Line 15: | ||
***[[Antinuclear antibody]] | ***[[Antinuclear antibody]] | ||
***[[Rheumatoid factor]] | ***[[Rheumatoid factor]] | ||
***Anticentromere antibody | ***[[Anti-centromere antibodies|Anticentromere antibody]] | ||
***[[Antiphospholipid | ***[[Antiphospholipid antibody]] | ||
***Serum [[creatinine]] | ***Serum [[creatinine]] | ||
***Complement | ***[[Complement]] | ||
***SCL-70 | ***SCL-70 | ||
**To rule out hypercoagulability: | **To rule out hypercoagulability: | ||
***[[Complete blood count]] | ***[[Complete blood count]] | ||
***[[Liver function]] test | ***[[Liver function]] test | ||
***PT, PTT and INR | ***[[Prothrombin time|PT]], [[Partial thromboplastin time|PTT]] and [[INR]] | ||
***Antiphospholipid antibodies | ***[[Antiphospholipid antibodies]] | ||
***Anticardiolipin antibodies | ***[[Anti-cardiolipin antibodies|Anticardiolipin antibodies]] | ||
***Protein C and S | ***[[Protein C]] and [[Protein S|S]] | ||
***Antithrombin III | ***[[Antithrombin III]] | ||
***Factor V Leiden | ***[[Factor V Leiden]] | ||
***Prothrombin gene mutation | ***[[Prothrombin gene mutation G20210A|Prothrombin gene mutation]] | ||
**Toxicology screen | **Toxicology screen | ||
***Cocaine | ***[[Cocaine]] | ||
***Amphetamine | ***[[Amphetamine]] | ||
***Cannabis | ***[[Cannabis]] | ||
Revision as of 18:41, 11 April 2018
|
Buerger's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Buerger's disease laboratory findings On the Web |
|
American Roentgen Ray Society Images of Buerger's disease laboratory findings |
|
Risk calculators and risk factors for Buerger's disease laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
There are no diagnostic laboratory findings associated with Buerger's disease. Lab testing is done to exclude other vasculitides, such as lupus, scleroderma and mixed connective tissue disease.
Laboratory Findings
- There are no diagnostic laboratory findings associated with Buerger's disease.
- Laboratory testing is performed to exclude other pathologies, and include:[1][2][3]
- Acute phase reactants that indicate an active inflammatory process:
- Immunologic panel to rule out autoimmune disease:
- To rule out hypercoagulability:
- Toxicology screen
References
- ↑ Olin JW (September 2000). "Thromboangiitis obliterans (Buerger's disease)". N. Engl. J. Med. 343 (12): 864–9. doi:10.1056/NEJM200009213431207. PMID 10995867.
- ↑ Maslowski L, McBane R, Alexewicz P, Wysokinski WE (2002). "Antiphospholipid antibodies in thromboangiitis obliterans". Vasc Med. 7 (4): 259–64. doi:10.1191/1358863x02vm452oa. PMID 12710840.
- ↑ Piazza G, Creager MA (April 2010). "Thromboangiitis obliterans". Circulation. 121 (16): 1858–61. doi:10.1161/CIRCULATIONAHA.110.942383. PMC 2880529. PMID 20421527.